Scancell (LON:SCLP) Stock Price Down 3.2% - Here's Why

Key Points

• Scancell Holdings plc (LON:SCLP) shares fell by 3.2% on Tuesday to GBX 9.69 ($0.13), with trading volume increasing by 44% from the average session.
• Insider Martin Diggle purchased 4,400,000 shares at an average cost of GBX 10, totaling £440,000, indicating confidence from company insiders.
• Scancell is a clinical stage immunotherapy biotech firm focusing on developing treatments for significant unmet cancer needs, including 'off-the-shelf' vaccines and monoclonal antibodies.

Scancell Holdings plc (LON:SCLP - ) shares traded down 3.2% on Tuesday . The stock traded as low as GBX 9.60 ($0.13) and last traded at GBX 9.69 ($0.13). 1,336,894 shares changed hands during mid-day trading, an increase of 44% from the average session volume of 925,977 shares. The stock had previously closed at GBX 10 ($0.13).

Scancell Stock Down 3.2%

The firm has a 50-day moving average of GBX 10.17 and a two-hundred day moving average of GBX 9.61. The company has a current ratio of 3.42, a quick ratio of 13.01 and a debt-to-equity ratio of -566.79. The firm has a market capitalization of £100.51 million, a PE ratio of -465.63 and a beta of 0.35.

Insider Buying and Selling

In related news, insider Martin Diggle acquired 4,400,000 shares of the business's stock in a transaction on Friday, August 1st. The shares were bought at an average cost of GBX 10 per share, with a total value of £440,000. 14.23% of the stock is owned by company insiders.

Scancell Company Profile

Scancell LSE: SCLP is a clinical stage immunotherapy biotech company developing treatments for significant unmet needs in cancer. We aim to translate our innovation and creativity into increased and durable responses in patients without compromising safety, addressing hard-to-treat cancers. Scancell has developed a pipeline of ‘off-the-shelf' vaccines to induce immune responses and highly tumour specific monoclonal antibodies to redirect immune cells or drugs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.